

NDA 208144/S-006

**SUPPLEMENT APPROVAL**

Bausch Health  
Attention: Shaun A. Mbithi  
Senior Manager, Regulatory Affairs  
400 Somerset Corporate Boulevard  
Bridgewater, NJ 08807

Dear Ms. Mbithi:

Please refer to your supplemental new drug application (sNDA) dated and received September 13, 2019, and your amendment, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lumify (brimonidine tartrate ophthalmic solution), 0.025%.

This “Prior Approval” supplemental new drug application provides for updated labeling on the single-dose unit (0.4 mL) package configuration to clarify the directions for use by adding “discard vial immediately after use” and to more clearly describe the number of vials contained in each trade and sample carton and pouch as “1 SINGLE-USE VIAL”.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the submitted labeling and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<b>Submitted Draft Labeling</b>	<b>Date Submitted</b>
0.4 mL (single dose) foil pouch (sample)	February 3, 2020
0.4 mL (single dose) carton (sample)	February 3, 2020
0.4 mL (single dose) vial (sample and trade)	September 13, 2019
0.4 mL (single dose) foil pouch (trade)	February 3, 2020
0.4 mL (single dose) carton (trade)	February 3, 2020

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.<sup>1</sup> For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 208144/S-006.**” Approval of this submission by FDA is not required before the labeling is used.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.<sup>2</sup> Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, call LCDR Jung Lee, Senior Regulatory Project Manager, at (301) 796-3599.

Sincerely,

*{See appended electronic signature page}*

Karen Murry Mahoney, MD, FACE  
Deputy Director (Acting), Office of Nonprescription Drugs  
Deputy Director (Acting), Division of Nonprescription Drugs II  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KAREN M MAHONEY  
03/05/2020 04:47:52 PM